Breast Cancer Screening and Axillary Adenopathy in the Era of COVID-19 Vaccination.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 36219117.
- Also identified by DOI 10.1148/radiol.222040 and PMC identifier 9580051.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 50-year-old woman with persistent axillary lymphadenopathy 17 weeks after COVID-19 vaccination was ultimately diagnosed with biopsy-proven benign reactive lymphadenopathy. In contrast, a 60-year-old woman with axillary lymphadenopathy and concurrent suspicious breast findings 9 weeks after COVID-19 vaccination was ultimately diagnosed with biopsy-proven metastatic breast carcinoma. This article reviews the current guidelines regarding breast cancer screening and management of axillary lymphadenopathy in the setting of COVID-19 vaccination.
Medical subject headings
- Breast Neoplasms
- COVID-19
- Lymphadenopathy